Antibiotic
Minocycline + Amiodarone for Atrial Fibrillation
This trial will test whether or not minocycline, a safe and common acne drug, is better at preventing atrial fibrillation than amiodarone, the current standard of care. If minocycline is found to be more effective, it could be incorporated into clinical care for this disease, improving outcomes and reducing costs.
Anticoagulant
Edoxaban for Atrial Fibrillation
This trial is testing if edoxaban, a daily blood-thinning medication, can safely reduce stroke risk in high-risk atrial fibrillation patients who have had previous brain bleeds. The goal is to see if it works better than not using any blood thinners or using simpler treatments. Edoxaban has been shown to be effective in preventing stroke with a lower risk of bleeding.
Procedure
Cryoablation + LAA Closure for Atrial Fibrillation
This trial is testing a new heart surgery technique that uses a freezing device to create scar tissue to block off abnormal electrical pathways in the heart, in addition to sealing off the left atrial appendage to prevent blood clots.
Popular Filters
Trials for AFib Patients
Behavioural Intervention
Exercise Training for Atrial Fibrillation
This trial will compare the effects of high-intensity interval training vs. moderate-intensity continuous exercise training in adults with persistent or permanent atrial fibrillation on exercise capacity and quality of life.
Procedure
Ablation Techniques for Atrial Fibrillation
This trial compares two methods of treating atrial fibrillation: one using a special technique to find specific problem areas in the heart and one without it. It targets patients whose condition hasn't improved with medication. The special technique aims to make the treatment more precise and effective.
Anticoagulant
Anticoagulation for Atrial Fibrillation Post-Ablation
This trial is comparing medical approaches for stroke prevention in people who have atrial fibrillation (AF) and have undergone a successful procedure called ablation to eliminate or substantially reduce the arrhythmia.
Trials for Stroke Patients
Anticoagulant
Anticoagulation for Atrial Fibrillation Post-Ablation
This trial is comparing medical approaches for stroke prevention in people who have atrial fibrillation (AF) and have undergone a successful procedure called ablation to eliminate or substantially reduce the arrhythmia.
Blood Collection Device Validation for Patients on Blood Thinners
This trial is for a medical device manufacturer to qualify their line of blood collection tubes with the FDA. Participants who are currently on anticoagulants will be compensated for their time and resources.
Anticoagulant
Anticoagulation + Antiplatelet Therapy for Post-Operative Atrial Fibrillation
This trial is looking at whether adding oral anticoagulation to background antiplatelet therapy is effective and safe in preventing thromboembolic events in patients who develop new-onset atrial fibrillation after isolated coronary artery bypass graft surgery.
Anticoagulant
Blood Thinners for Atrial Fibrillation
This trial is testing whether taking blood-thinning pills can prevent strokes and other heart issues in patients who have temporary irregular heartbeats and are at risk of stroke after surgery. These pills are a recent breakthrough in preventing strokes.
Anticoagulant
Apixaban vs Aspirin for Stroke Prevention in Atrial Fibrillation After Brain Bleed
This trial is testing whether apixaban is better than aspirin at preventing strokes or death in patients who have recently had a bleed in the brain and also have atrial fibrillation.
Phase 3 Trials
Anticoagulant
Anticoagulation + Antiplatelet Therapy for Post-Operative Atrial Fibrillation
This trial is looking at whether adding oral anticoagulation to background antiplatelet therapy is effective and safe in preventing thromboembolic events in patients who develop new-onset atrial fibrillation after isolated coronary artery bypass graft surgery.
Anticoagulant
Apixaban vs Aspirin for Stroke Prevention in Atrial Fibrillation After Brain Bleed
This trial is testing whether apixaban is better than aspirin at preventing strokes or death in patients who have recently had a bleed in the brain and also have atrial fibrillation.
Anticoagulant
Smartwatch-Guided DOAC Therapy for Atrial Fibrillation
This trial tests whether taking blood-thinning medication continuously or only when a smart watch detects an irregular heartbeat is better for adults with a history of irregular heartbeats and moderate stroke risk.
Factor Xa Inhibitor
Milvexian vs Apixaban for Atrial Fibrillation
This trial is testing a new medication called milvexian to see if it can prevent strokes and blood clots as well as an existing drug, apixaban. Apixaban (Eliquisâ„¢) was developed by Bristol-Myers Squibb and Pfizer and has been approved for the prevention of stroke in patients with certain heart conditions. The study focuses on patients who are at risk of these serious conditions. Milvexian works by helping to keep the blood flowing smoothly, reducing the chances of dangerous clots forming.
Trials With No Placebo
Behavioural Intervention
Exercise Training for Atrial Fibrillation
This trial will compare the effects of high-intensity interval training vs. moderate-intensity continuous exercise training in adults with persistent or permanent atrial fibrillation on exercise capacity and quality of life.
Procedure
Ablation Techniques for Atrial Fibrillation
This trial compares two methods of treating atrial fibrillation: one using a special technique to find specific problem areas in the heart and one without it. It targets patients whose condition hasn't improved with medication. The special technique aims to make the treatment more precise and effective.
Anticoagulant
Anticoagulation for Atrial Fibrillation Post-Ablation
This trial is comparing medical approaches for stroke prevention in people who have atrial fibrillation (AF) and have undergone a successful procedure called ablation to eliminate or substantially reduce the arrhythmia.
View More Related Trials
Frequently Asked Questions
Introduction to atrial fibrillation
What are the top hospitals conducting atrial fibrillation research?
When it comes to advancing the treatment options for atrial fibrillation, several hospitals are leading the way. Massachusetts General Hospital in Boston is at the forefront with nine active clinical trials focused on this heart condition. With a remarkable history of 61 completed atrial fibrillation trials dating back to their first recorded trial in 2003, this renowned institution is making significant strides toward improving patients' lives. In Canada's capital city, the University of Ottawa Heart Institute has also emerged as a key player in atrial fibrillation research. They currently have nine ongoing trials and have conducted 29 studies since initiating their first trial in 2000.
Further north, the Montreal Heart Institute has achieved notable progress with six active clinical trials and a total of 26 previous investigations dedicated to understanding and treating atrial fibrillation since recording their inaugural trial twenty years ago. Meanwhile, Grandview Medical Center in Birmingham may be newer to the scene but is already making an impact with six ongoing clinical trials that focus on this irregular heartbeat disorder; they commenced their first study just eight years ago,in2013.
Lastly,Cleveland Clinic located at Cleveland joins these esteemed institutions with five current atrial fibrillation clinical trials under its belt along with twenty-eight prior studies from its outset nineteen years ago,in1999.Their collective efforts showcase dedication and innovation as they strive towards finding better solutions for those affected by this common cardiac condition.
These hospitals serve as beacons of hope for individuals living with or at risk of developing atrial fibrillation. Through cutting-edge research and collaborative efforts among healthcare professionals, breakthroughs are being made every day that bring us closer to improved treatments and management strategies for this complex heart rhythm disorder
Which are the best cities for atrial fibrillation clinical trials?
When it comes to atrial fibrillation clinical trials, several cities lead the way in advancing research and treatment options. New york, with its 28 active trials, focuses on innovative approaches like Pulse Field Ablation and the WATCHMAN FLX Implant. Montreal follows closely behind with 23 ongoing studies exploring Catheter ablation and medications such as Apixaban and Acetylsalicylic acid (ASA). Boston also plays a significant role with 21 active trials investigating therapies like Antiplatelet Therapy and Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder). Toronto and Ottawa are other notable cities contributing to this field of study. These cities offer individuals with atrial fibrillation access to cutting-edge clinical trials that pave the way for improved management of this condition.
Which are the top treatments for atrial fibrillation being explored in clinical trials?
Clinical trials are shedding light on the top treatments being explored for atrial fibrillation. Among these potential options, intervention takes the lead with four active trials and a history of two all-time atrial fibrillation trials since its inception in 2012. Apixaban follows closely behind, participating in two ongoing studies and contributing to a total of 47 clinical trials focused on atrial fibrillation since its introduction in 2007. Catheter ablation also shows promise, joining apixaban with two active trials and an impressive record of 28 all-time atrial fibrillation trials dating back to 2009. Additionally, amiodarone emerges as another contender with two current research endeavors and involvement in 34 all-time clinical trials targeting atrial fibrillation after its debut in 1998. Lastly, a novel approach emerges—12-week supervised exercise-based cardiac rehabilitation program—with one ongoing trial marking the first exploration into this innovative treatment option in early 2022.
What are the most recent clinical trials for atrial fibrillation?
Exciting advancements are taking place in the field of atrial fibrillation as recent clinical trials explore potential breakthrough treatments. One such trial focuses on the use of stellate ganglion block, investigating its effectiveness in managing atrial fibrillation. Another study examines an as-needed rate control approach to treating this condition. Additionally, research is underway to assess the efficacy of Asundexian and colchicine arm for atrial fibrillation patients. Furthermore, a phase 4 trial evaluates the benefits of oral anticoagulants specifically tailored to individuals with atrial fibrillation. These trials offer hope for improved management and treatment options for those living with this cardiovascular disorder.
What atrial fibrillation clinical trials were recently completed?
In the realm of atrial fibrillation, several noteworthy clinical trials have recently concluded, paving the way for advancements in treatment. The St. Vincent Cardiovascular Research Institute wrapped up a trial investigating Colchicine in May 2021, while Wake Forest University Health Sciences completed their Methohexital study in April 2020. Furthermore, Allergan's AGN-151607 trial reached completion milestone back in March 2019. Additionally, the Population Health Research Institute conducted a Colchicine trial which finished in February 2018. These significant research endeavors contribute to our understanding and potential management options for atrial fibrillation patients on their journey towards improved heart health.